Celcuity Inc. (CELC)

NASDAQ: CELC · IEX Real-Time Price · USD
-0.10 (-0.90%)
Jun 5, 2023, 12:14 PM EDT - Market open

Company Description

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States.

The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.

Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer.

The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells.

It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib.

Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Celcuity Inc.
Celcuity logo
Country United States
Founded 2011
IPO Date Sep 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 45
CEO Brian F. Sullivan

Contact Details

16305 36th Avenue N, Suite 100
Minneapolis, Minnesota 55446
United States
Phone 763-392-0767
Website celcuity.com

Stock Details

Ticker Symbol CELC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001603454
CUSIP Number 15102K100
ISIN Number US15102K1007
SIC Code 8071

Key Executives

Name Position
Brian F. Sullivan Co-Founder, Chairman and Chief Executive Officer
Dr. Lance G. Laing Ph.D. Co-Founder, Chief Science Officer, Vice President, Secretary and Director
Vicky Hahne Chief Financial Officer
Dr. John R. MacDonald Dabt, Ph., Ph.D. Senior Vice President of Research & Development
Sheri Smith Acting Head of Clinical Operations
Igor Gorbatchevsky M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
May 16, 2023 S-8 Securities to be offered to employees in employee benefit plans
May 15, 2023 10-Q Quarterly Report
May 15, 2023 8-K Current Report
May 12, 2023 8-K Current Report
May 2, 2023 D/A Filing
Apr 7, 2023 10-K/A [Amend] Annual report
Apr 4, 2023 ARS Filing
Mar 31, 2023 DEF 14A Other definitive proxy statements
Mar 31, 2023 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 23, 2023 10-K Annual Report